Clinical Trial Update: Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating sitagliptin to prevent new-onset diabetes after kidney transplant has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttransplant Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Posttransplant Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2021-06-29